Log In
Print this Print this

Strimvelis (2696273, GSK2696273)

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionRetroviral vector delivering adenosine deaminase (ADA) for ex vivo hematopoietic stem cell therapy
Molecular Target Adenosine deaminase (ADA)
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector
Latest Stage of DevelopmentApproved
Standard Indication Metabolic (unspecified)
Indication DetailsTreat severe combined immunodeficiency (SCID) due to adenosine deaminase deficiency (ADA-SCID)
Regulatory Designation
PartnerFondazione Telethon;
San Raffaele Hospital

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today